LONDON — GSK announced on Monday that Luke Miels, the company’s chief commercial officer, will take over as CEO on January 1, succeeding Emma Walmsley, who has led the company since 2017.
Walmsley’s leadership was marked by significant strategic shifts, including the spinoff of GSK’s consumer healthcare business into a new entity, Haleon, and a renewed focus on innovative medicines, particularly specialty drugs and vaccines, aimed at driving future growth.
However, her tenure has not been without scrutiny. Investors have raised concerns regarding GSK’s competitive positioning, especially as the company faces the impending loss of patent protection on its established HIV treatments and navigates challenges within its vaccine segment. In a landscape where rival firms have gained momentum, GSK has seen its stock performance stagnate over the past year, raising questions about its long-term strategy.
Use the database as your supply chain compass →
